Tevogen Inc. (TVGN)
NASDAQ: TVGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TVGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $405.20M
- EPS (TTM)
- -$7.01
- Dividend yield
- None
- 52-week range
- 3.64 – 24.90
- Day range
- 5.72 – 6.35
- Volume / Avg
- 9.35K / 7.94K
- Beta
- —
- Shares outstanding
- 68.68M
52-week range
TVGN stock today
Shares of Tevogen (TVGN) finished lower on Nov 20 at $5.90, a drop of 6.35% or $0.40 per share, versus the S&P 500's 3.70% decline. Shares are 76.3% below their 52-week high of $24.90, set on Nov 26, 2025 and 62.3% above the 52-week low of $3.64, near the bottom of the past year's range. TVGN is down 64.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 73.8%.
Tevogen has posted a net loss over the last twelve months (EPS of -$7.01), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tevogen
Company profileTevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Ryan H. Saadi M.D., M.P.H.
- Headquarters
- Warren, NJ
- Employees
- 18
- IPO year
- 2022
- Website
- tevogen.com
Financial highlights
Full financialsTevogen reported a net loss of $26.3 million, compared with a loss of $13.7 million a year earlier. Diluted earnings per share came in at -$8.08.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Growth | — | — | — | — |
| Net income | $-26.28M | $-13.73M | $-60.48M | $4.41M |
| EPS (diluted) | $-8.08 | $-3.50 | $-2.44 | — |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-1.76 vs —
TVGN news
All TVGN news- Tevogen Highlights Significant Liability Reduction and Continued Insider ControlGlobeNewswire
- Tevogen Complements Capital Access with Two-Year Extension to Loan AgreementGlobeNewswire
- UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLCGlobeNewswire
- Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLCGlobeNewswire
Tevogen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs TVGN |
| CADLCandel Therapeutics Inc. | 5.04 | -1.75% | $395.37M | vs TVGN |
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs TVGN |
| IRLAIRulya Therapeutics Inc. | 39.88 | -0.15% | $432.36M | vs TVGN |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs TVGN |
| ALECAlector Inc. | 2.34 | +1.52% | $347.63M | vs TVGN |
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs TVGN |
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs TVGN |
Indexes, lists and sector
Tevogen stock FAQ
What is Tevogen's stock price today?
TVGN last traded at $5.90 as of Nov 20, 4:00 PM EST, down 6.35% on the day. Prices are delayed at least 15 minutes.
Does Tevogen pay a dividend?
No. Tevogen does not currently pay a regular cash dividend.
Who is Tevogen's CEO?
Dr. Ryan H. Saadi M.D., M.P.H. is the chief executive officer of Tevogen Inc., which has about 18 employees.
Has TVGN ever split its stock?
Yes. The most recent TVGN stock split was a 1-for-50 split on Mar 6, 2026.
What is the TVGN 52-week high?
The 52-week high for TVGN is $24.90 and the 52-week low is $3.64. The stock is currently 76.3% below its high.